Premium
Expression of mTOR signaling pathway markers in prostate cancer progression
Author(s) -
Kremer Celeste L.,
Klein Rob R.,
Mendelson Jenny,
Browne Walden,
Samadzedeh Linda K.,
Vanpatten Kristie,
Highstrom Lindsey,
Pestano Gary A.,
Nagle Raymond B.
Publication year - 2006
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20410
Subject(s) - pten , pi3k/akt/mtor pathway , prostate cancer , cancer research , prostate , cancer , immunohistochemistry , medicine , tissue microarray , pathology , biology , signal transduction , microbiology and biotechnology
BACKGROUND The PI3K/AKT/mTOR pathway is central to prostate cancer progression. A preliminary investigation of immuno‐histochemical expression of mammalian target of rapamycin (mTOR) pathway markers was undertaken to identify patterns of expression in prostate tissue. METHODS Immunohistochemistry was performed on a custom‐made prostate tissue array. Mean long scores and variability of long scores for each marker were recorded for normal lumenal cells, prostate intraepithelial neoplasia (PIN), and cancer. RESULTS Expression of PTEN decreased and mTOR signaling pathway markers increased in PIN and in cancer as compared to normal cells in the majority of samples. Overexpression of 4E‐BP1 and p‐4E‐BP1 was observed in PIN and cancer. However, in cancer, the overexpression of 4E‐BP1 was significantly higher than with any other marker. DISCUSSION Results suggest that 4E‐BP1 overexpression is strongly associated with prostate cancer, especially when combined with PTEN and mTOR expression data. Hierarchical clustering analysis utilizing PTEN, mTOR, and 4E‐BP1 separated normal from cancer cell populations in most cases. Prostate © 2006 Wiley‐Liss, Inc.